CL2014001984A1 - Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos. - Google Patents

Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos.

Info

Publication number
CL2014001984A1
CL2014001984A1 CL2014001984A CL2014001984A CL2014001984A1 CL 2014001984 A1 CL2014001984 A1 CL 2014001984A1 CL 2014001984 A CL2014001984 A CL 2014001984A CL 2014001984 A CL2014001984 A CL 2014001984A CL 2014001984 A1 CL2014001984 A1 CL 2014001984A1
Authority
CL
Chile
Prior art keywords
synuclein
production method
humanized antibodies
recognize alpha
alpha
Prior art date
Application number
CL2014001984A
Other languages
English (en)
Inventor
Jose Saldanha
Tarlochan Nijjar
Original Assignee
Neotope Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotope Biosciences Ltd filed Critical Neotope Biosciences Ltd
Publication of CL2014001984A1 publication Critical patent/CL2014001984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2014001984A 2012-01-27 2014-07-25 Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos. CL2014001984A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261591835P 2012-01-27 2012-01-27
US201261711207P 2012-10-08 2012-10-08

Publications (1)

Publication Number Publication Date
CL2014001984A1 true CL2014001984A1 (es) 2014-12-19

Family

ID=48873980

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001984A CL2014001984A1 (es) 2012-01-27 2014-07-25 Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos.

Country Status (23)

Country Link
US (7) US8790644B2 (es)
EP (1) EP2807188B1 (es)
JP (2) JP6342333B2 (es)
KR (2) KR102086061B1 (es)
CN (2) CN108517010A (es)
AU (1) AU2013211874B2 (es)
BR (1) BR112014018561A8 (es)
CA (1) CA2863953A1 (es)
CL (1) CL2014001984A1 (es)
DK (1) DK2807188T3 (es)
ES (1) ES2749457T3 (es)
HK (1) HK1204791A1 (es)
IL (2) IL233829B (es)
IN (1) IN2014DN07149A (es)
MX (2) MX360778B (es)
MY (1) MY171140A (es)
NZ (1) NZ629296A (es)
PH (1) PH12014501685A1 (es)
RU (1) RU2642262C2 (es)
SG (1) SG11201404321YA (es)
UA (1) UA115439C2 (es)
WO (1) WO2013112945A1 (es)
ZA (1) ZA201406227B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
KR20230073341A (ko) * 2013-07-05 2023-05-25 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
CN111499743B (zh) * 2013-11-21 2024-01-12 豪夫迈·罗氏有限公司 抗-α-突触核蛋白抗体及使用方法
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
CN106568969B (zh) * 2016-10-19 2017-09-26 首都医科大学 一种丝氨酸129位磷酸化alpha‑突触核蛋白聚集体的ELISA检测方法
WO2018102763A1 (en) * 2016-12-02 2018-06-07 Prothena Biosciences Limited Infrared assay detecting secondary structure profiles of alpha-synuclein
CA3051839A1 (en) * 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3406632A1 (en) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Ligands binding to prion protein for use in the treatment of synucleinopathies
CN116731173A (zh) * 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
AU2019247511A1 (en) 2018-04-06 2020-10-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CN112839710A (zh) 2018-08-09 2021-05-25 霍夫曼-拉罗奇有限公司 帕金森氏病的确定
US20210347868A1 (en) * 2018-10-19 2021-11-11 Gabriel Pascual Anti-synuclein antibodies
JP2022551603A (ja) 2019-10-03 2022-12-12 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
IL296664A (en) 2020-04-24 2022-11-01 Hoffmann La Roche Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
JP2023535024A (ja) * 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1996024369A1 (en) 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE490518T1 (de) 1999-02-05 2010-12-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zum wiederauffinden von texturbildern
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
CA2485342A1 (en) * 2002-05-13 2004-05-13 Alexion Pharmaceuticals, Inc. Humanized antibodies against the venezuelan equine encephalitis virus
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
WO2008103472A2 (en) * 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
RU2332986C2 (ru) 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1820022B1 (en) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
US7930064B2 (en) * 2004-11-19 2011-04-19 Parata Systems, Llc Automated drug discrimination during dispensing
EP1915177A4 (en) 2005-07-19 2011-08-31 Univ Rochester ALPHA-SYNUCLEIN ANTIBODIES AND RELATED TECHNIQUES
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
PT2126093E (pt) 2007-03-02 2012-12-03 Boehringer Ingelheim Pharma Melhoramento da produção de proteínas
US20100260766A1 (en) 2007-03-22 2010-10-14 Arvind Srivastava Stable antibody formulations
RS53402B (en) 2007-03-22 2014-10-31 Genentech, Inc. APPLICATION OF APOPTOTIC ANTI-IGE ANTIBODIES FOR MEMBRANE IGE
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
MX2010006395A (es) 2007-12-21 2010-07-01 Hoffmann La Roche Formulacion de anticuerpos.
NZ586875A (en) 2007-12-28 2012-10-26 Elan Pharm Inc Treatment and prophylaxis of amyloidosis with an antibody that binds a specific epitope of human amyloid A peptide
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
DE102008048129A1 (de) 2008-09-20 2010-04-22 Lfk-Lenkflugkörpersysteme Gmbh Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper
PL2949666T3 (pl) 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Ludzkie przeciwciała przeciwko alfa-synukleinie
ES2668079T3 (es) 2009-07-28 2018-05-16 Shire Human Genetic Therapies Composiciones y métodos para tratar la enfermedad de Gaucher
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20130116413A1 (en) 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011127324A2 (en) * 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
CN114246952A (zh) * 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
KR101846590B1 (ko) * 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 항 ｔｉｍ-3 항체
CN103153331B (zh) * 2010-07-15 2017-03-22 亚德赫伦医疗公司 靶向于钙粘着蛋白‑11的ec1结构域的人源化抗体及相关组合物和方法
JP6023715B2 (ja) 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド タンパク質の精製方法
CA2825791A1 (en) 2011-02-07 2012-08-16 Neotope Biosciences Limited Apoe immunotherapy
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
AU2012272815B2 (en) 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
CN108704132A (zh) 2011-10-31 2018-10-26 弗·哈夫曼-拉罗切有限公司 抗体制剂
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
RS58928B1 (sr) 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
PH12014501685A1 (en) 2014-11-10
KR102086061B1 (ko) 2020-03-11
US20150056187A1 (en) 2015-02-26
ES2749457T3 (es) 2020-03-20
US8790644B2 (en) 2014-07-29
CN104619724A (zh) 2015-05-13
MY171140A (en) 2019-09-27
US20200277362A1 (en) 2020-09-03
MX2018014044A (es) 2021-12-08
MX360778B (es) 2018-11-16
WO2013112945A1 (en) 2013-08-01
EP2807188B1 (en) 2019-09-11
US20180016329A1 (en) 2018-01-18
EP2807188A4 (en) 2015-07-01
IL281731A (en) 2021-05-31
US9234031B2 (en) 2016-01-12
ZA201406227B (en) 2016-02-24
IN2014DN07149A (es) 2015-04-24
AU2013211874A1 (en) 2014-09-18
SG11201404321YA (en) 2014-08-28
KR20200027570A (ko) 2020-03-12
JP2018148911A (ja) 2018-09-27
US10875909B2 (en) 2020-12-29
RU2642262C2 (ru) 2018-01-24
NZ629296A (en) 2016-06-24
US10118960B2 (en) 2018-11-06
DK2807188T3 (da) 2019-10-07
US20150024433A1 (en) 2015-01-22
US10597441B2 (en) 2020-03-24
HK1204791A1 (en) 2015-12-04
BR112014018561A2 (es) 2017-06-20
CN108517010A (zh) 2018-09-11
US20190153080A1 (en) 2019-05-23
BR112014018561A8 (pt) 2017-07-11
CN104619724B (zh) 2018-05-04
EP2807188A1 (en) 2014-12-03
UA115439C2 (uk) 2017-11-10
IL233829B (en) 2021-04-29
JP6342333B2 (ja) 2018-06-13
JP2015508062A (ja) 2015-03-16
KR20140125409A (ko) 2014-10-28
MX2014008952A (es) 2015-02-20
IL233829A0 (en) 2014-09-30
US9217030B2 (en) 2015-12-22
JP6807893B2 (ja) 2021-01-06
US20130266517A1 (en) 2013-10-10
US20160251416A1 (en) 2016-09-01
KR102246217B1 (ko) 2021-04-29
AU2013211874B2 (en) 2017-11-02
CA2863953A1 (en) 2013-08-01
US9670273B2 (en) 2017-06-06
RU2014134747A (ru) 2016-03-20

Similar Documents

Publication Publication Date Title
CL2014001984A1 (es) Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos.
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
CO7020875A2 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
HK1212710A1 (zh) 用於選擇針對 的抗體的方法
DK3016681T5 (da) Humaniserede eller kimære CD3-antistoffer
DK3083694T3 (da) Caniniserede, murine anti-canin-pd-1-antistoffer
CO6980627A2 (es) Anticuerpos anti-pfh-tau y sus usos
PT3088517T (pt) Anticorpo monoclonal neutralizante anti-il-33 humano
DK2847231T3 (da) Multispecifikke monoklonale antistoffer
DK3336106T3 (da) Anti-fcrh5-antistoffer
DK3156416T3 (da) Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer
GB201319161D0 (en) Multivalent antigen-binding protein molecules
DK3071595T3 (da) Humaniseret anti-kallikrein-2-antistof
BR112014028457A2 (pt) anticorpos anti-fcrn
PT3004163T (pt) Método para purificação de anticorpo
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK2817333T3 (da) Bispecifikke, asymmetriske igg4-antistoffer
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
DK3083680T3 (da) Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
CL2014002616A1 (es) Anticuerpos anti-baff-anti-il-17 biespecíficos; composiciones que lo contienen y sus usos.
EP2995679A4 (en) PROCESS FOR PREPARING MONOCLONAL IGA ANTIBODIES
DK2943261T3 (da) Flertrins-separationsfremgangsmåde
GB201522391D0 (en) Antibody molecules
DK3068800T3 (da) FcRn-specifikke antistoffer
CL2014002204A1 (es) Formulacion de anticuerpo anti il-17 y sus usos.